Overview

Desidustat in the Management of COVID-19 Patients

Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This study is a Phase 2b, Multicenter, Open-label, Randomized, Comparator- Controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet for the Management of mild, moderate and severe COVID-19 patients. 100 mg of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.
Phase:
Phase 2
Details
Lead Sponsor:
Cadila Healthcare Limited